



ASX ANNOUNCEMENT

5 APRIL 2024

US PATENT ALLOWED FOR CHM 0201 (CORE-NK) PLATFORM TECHNOLOGY

Sydney, Australia, 5 April 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the US Patent & Trademark Office has allowed for issuance of a patent application covering the CHM 0201 (CORE-NK) technology used to manufacture Chimeric’s clinical-stage universal NK cell asset CHM 0201 and preclinical-stage NK cell assets CHM 0301, CHM 1301, and CHM 2301.

The allowed patent application 16/614,132, entitled “Compositions for Expanding Natural Killer Cells,” is expected to provide patent protection until 2039.

Chimeric holds the exclusive worldwide license to develop and commercialize the allowed patent and related patent applications filed in other global territories for oncology, immune disorders, and infectious diseases.

Chimeric’s CEO and Managing Director Jennifer Chow said: “We are delighted with USPTO’s decision to grant patent protection for our CORE-NK platform in the United States, the single largest global market for biopharmaceutical products. The allowance of this first US patent application lays the foundation for the intellectual property portfolio supporting our best-in-class pipeline of allogeneic NK cell assets.”

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.



CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM 0201 in combination regimens have been initiated. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow

Chief Executive Officer and Managing Director

Chimeric Therapeutics

T: + 1 9087238387

E: jchow@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Paul Hopper

Executive Chairman

Chimeric Therapeutics

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au